Escherichia coli clinical trials
How each study uses Escherichia coli is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Escherichia coli studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 5
Xiamen Innovax Biotech Co., Ltd (6) · Beijing Health Guard Biotechnology, Inc (5) · University Hospital, Linkoeping (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · Jun Zhang (1) · NIZO Food Research (1) · International Vaccine Institute (1) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1)
Studies
Open first, then newest update. How each study uses Escherichia coli is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Safety and Immunogenicity of Hecolin® in Healthy Pregnant WomenRecruitingPhase 2International Vaccine InstituteNCT05808166Written as Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).How we know
- Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)RecruitingPhase 1Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06314880Written as Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)How we know
- Individual Differences in Acute Response to Experimental Inflammation: Microcirculatory Changes and Psychological PredictorsCompletedNot applicableUniversity Hospital, LinkoepingNCT06618716Written as endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)How we know
- Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and AboveCompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT06564116Written as Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)How we know
- A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) VaccineActive, not recruitingPhase 3Beijing Health Guard Biotechnology, IncNCT06207175Written as Nonavalent HPV study vaccineHow we know
- A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV VaccineCompletedPhase 2Beijing Health Guard Biotechnology, IncNCT05694728Written as Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)How we know
- A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV VaccineCompletedPhase 1Beijing Health Guard Biotechnology, IncNCT05680454Written as Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)How we know
- A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV VaccineStatus unknownPhase 3Beijing Health Guard Biotechnology, IncNCT05668572Written as Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)How we know
- A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in ChinaActive, not recruitingPhase 3Beijing Health Guard Biotechnology, IncNCT05662020Written as Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)How we know
- Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy FemaleCompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT05426148Written as Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®How we know
- A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy AdultsCompletedPhase 1Jiangsu Province Centers for Disease Control and PreventionNCT03966040Written as Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7How we know
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)CompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT03365921Written as Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.How we know
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )CompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT02964910Written as Recombinant Hepatitis E Vaccine (Escherichia Coli)How we know
- A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)CompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT03168412Written as Recombinant Hepatitis E Vaccine (Escherichia Coli)How we know
- Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®)CompletedPhase 4Jun ZhangNCT02189603Written as Recombinant (E. Coli) Hepatitis E VaccineHow we know
- Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. ColiCompletedNot applicableNIZO Food ResearchNCT02541695Written as E. coli strain E1392-75-2AHow we know
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)CompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT02417597Written as Recombinant Hepatitis E Vaccine (Escherichia Coli)How we know
Given beside what is tested · 1 — Escherichia coli is usual care or a partner of the new treatment
Codes
What other systems call Escherichia coli · ClinicalTrials.gg INT014965
- UNII (FDA) 514B9K0L10ESCHERICHIA COLIConfirmed FDA, Wikidata
- RxNorm 350202One source FDA
- Wikidata Q25419Escherichia coliConfirmed FDA, Wikidata
- NCI Thesaurus C14206Escherichia coliOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 514B9K0L10 | ESCHERICHIA COLI | Confirmed FDA, Wikidata |
| RxNorm | 350202 | — | One source FDA |
| Wikidata | Q25419 | Escherichia coli | Confirmed FDA, Wikidata |
| NCI Thesaurus | C14206 | Escherichia coli | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.